About Cidara Therapeutics, Inc.
https://www.cidara.comCidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
CEO
Jeffrey L. Stein
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-24 | Reverse | 1:20 |
ETFs Holding This Stock
VTS.AX
Weight:0.01%
Shares:760.14K
SCHA
Weight:0.13%
Shares:116.07K
R2US.L
Weight:0.14%
Shares:30.51K
Summary
Showing Top 3 of 72
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
WBB Securities
Strong Buy
JMP Securities
Market Outperform
RBC Capital
Outperform
Cantor Fitzgerald
Overweight
Guggenheim
Neutral
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:3.37M
Value:$745.06M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:3.02M
Value:$668.79M
BB BIOTECH AG
Shares:2.3M
Value:$508.13M
Summary
Showing Top 3 of 179
About Cidara Therapeutics, Inc.
https://www.cidara.comCidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $43.63M ▲ | $-83.23M ▼ | 0% | $-3.1 ▼ | $-83.2M ▼ |
| Q2-2025 | $0 | $27.38M ▲ | $-25.72M ▼ | 0% | $-1.65 ▲ | $-27.36M ▼ |
| Q1-2025 | $0 | $25.27M ▼ | $-23.48M ▲ | 0% | $-1.66 ▲ | $-25.22M ▲ |
| Q4-2024 | $0 | $54.18M ▲ | $-52.31M ▼ | 0% | $-5.37 ▼ | $-54.12M ▼ |
| Q3-2024 | $0 | $17.39M | $-15.98M | 0% | $-2.38 | $-17.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $293.65M ▼ | $518.65M ▼ | $96.26M ▲ | $422.39M ▼ |
| Q2-2025 | $510.57M ▲ | $534.33M ▲ | $33.15M ▼ | $501.17M ▲ |
| Q1-2025 | $168.15M ▼ | $191.73M ▼ | $50.05M ▼ | $141.68M ▼ |
| Q4-2024 | $189.82M ▲ | $214.8M ▲ | $51.49M ▲ | $163.31M ▲ |
| Q3-2024 | $127.39M | $162.33M | $46.7M | $115.63M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-83.23M ▼ | $-40.62M ▲ | $-176.47M ▼ | $160K ▼ | $-216.93M ▼ | $-40.62M ▲ |
| Q2-2025 | $-25.72M ▼ | $-40.96M ▼ | $0 ▼ | $383.38M ▲ | $342.42M ▲ | $-40.96M ▼ |
| Q1-2025 | $-23.48M ▲ | $-21.95M ▲ | $185K ▲ | $77K ▼ | $-21.69M ▼ | $-21.95M ▲ |
| Q4-2024 | $-52.31M ▼ | $-29.41M ▲ | $0 ▲ | $98.2M ▲ | $68.79M ▲ | $-29.41M ▲ |
| Q3-2024 | $-12.98M | $-36.7M | $-106K | $-182K | $-36.98M | $-36.8M |
Revenue by Products
| Product | Q1-2021 | Q2-2021 | Q2-2023 |
|---|---|---|---|
 Collaboration Revenue | $0 ▲ | $30.00M ▲ | $10.00M ▼ |
CEO
Jeffrey L. Stein
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-24 | Reverse | 1:20 |
ETFs Holding This Stock
VTS.AX
Weight:0.01%
Shares:760.14K
SCHA
Weight:0.13%
Shares:116.07K
R2US.L
Weight:0.14%
Shares:30.51K
Summary
Showing Top 3 of 72
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
WBB Securities
Strong Buy
JMP Securities
Market Outperform
RBC Capital
Outperform
Cantor Fitzgerald
Overweight
Guggenheim
Neutral
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:3.37M
Value:$745.06M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:3.02M
Value:$668.79M
BB BIOTECH AG
Shares:2.3M
Value:$508.13M
Summary
Showing Top 3 of 179